Potential Link Between Proprotein Convertase Subtilisin/Kexin Type 9 and Alzheimer's Disease

Area of Science:

• Neurodegenerative diseases
• Cardiovascular risk factors
• Molecular biology

Background:

• Alzheimer's disease (AD) is a prevalent, incurable neurodegenerative disorder.
• Proprotein convertase subtilisin/kexin-9 (PCSK9) regulates low-density lipoprotein (LDL) receptor expression.
• PCSK9 is implicated in metabolic and cardiovascular risk factors associated with AD.

Purpose of the Study:

• To review indirect evidence suggesting a link between PCSK9 levels and Alzheimer's disease.
• To explore how PCSK9 influences AD risk factors such as metabolic dysfunction and hypertension.

Main Methods:

• Literature review of existing studies on PCSK9, AD, and related risk factors.
• Analysis of indirect associations between PCSK9 and AD pathogenesis.
• Examination of demographic factors influencing PCSK9 and AD prevalence.

Main Results:

• PCSK9 influences metabolic conditions (glucose intolerance, insulin resistance, obesity) and hypertension, known AD risk factors.
• PCSK9 levels are affected by age, sex, and ethnicity, which are also associated with AD.
• Indirect evidence suggests a potential role for PCSK9 in AD development.

Conclusions:

• PCSK9 represents a potential, yet unproven, link to Alzheimer's disease.
• Further research is warranted to elucidate the direct role of PCSK9 in AD pathogenesis.
• Targeting PCSK9 pathways could offer novel therapeutic or preventative strategies for AD.